David A. Siegel Aadi Bioscience, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 61,686 shares of AADI stock, worth $122,138. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,686
Previous 31,600
95.21%
Holding current value
$122,138
Previous $65,000
198.46%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AADI
# of Institutions
57Shares Held
15.6MCall Options Held
15KPut Options Held
3.1K-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.64 Million0.13% of portfolio
-
Qvt Financial LP New York, NY2.31MShares$4.58 Million0.72% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.1MShares$4.16 Million4.12% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.66 Million8.31% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.15MShares$2.27 Million1.96% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $41.6M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...